Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically-Based Pharmacokinetic Modeling and Clinical Observation.

Clinical pharmacology and therapeutics - 1 Mar 2025

Jang Yoo Jin, Kim Doh Kwan, Lim Shinn-Won, Hong Eunjin

Abstract excerpt

Escitalopram is commonly prescribed for depressive and anxiety disorders in elderly patients, who often show variable drug responses and face higher risks of side effects due to age-related changes in organ function. The CYP2C19 polymorphism may further affect escitalopram pharmacokinetics in elderly patients, complicating dose optimization for this group. Previous pharmacogenetic studies examining the impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antidepressive Agents, Second-Generation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Citalopram

Share to Computer Simulation

Share to Cytochrome P-450 CYP2C19

Share to Major Depressive Disorder

Share to Models, Biological

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 39717930
DOI: 10.1002/cpt.3537

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically-Based Pharmacokinetic Modeling and Clinical Observation.PMID 39717930Read ↗

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.Semantic proximity Read ↗

Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.Semantic proximity Read ↗

A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.Semantic proximity Read ↗

Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.Semantic proximity Read ↗

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.Semantic proximity Read ↗

Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.Semantic proximity Read ↗

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.Semantic proximity Read ↗

Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort StudySemantic proximity Read ↗

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.Semantic proximity Read ↗

Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.Semantic proximity Read ↗

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.